Lung Diseases Cies Search Engine [selected websites]


Blog Archive

Sep 17, 2008

Compugen : Peptide Drug Candidate for Treatment of Solid Tumor Cancers and Positive In Vivo Results

September 16, 2008 – Compugen Ltd. (NASDAQ: CGEN) announced that its proprietary DAC Blockers Discovery Platform has led to the discovery of CGEN-25008, a novel peptide antagonist of the Clusterin protein. Compugen also announced that recently analyzed in vitro and initial in vivo results from cell-based assays and a lung cancer mouse model indicate that CGEN-25008 reduces the growth rate of several cancer cell lines and significantly enhances the anti-cancer activity of Taxol™, a frequently used cancer chemotherapeutic drug.
Compugen’s DAC Blockers Platform was designed to predict peptides that can block proteins of interest from achieving certain disease-associated three-dimensional conformations. This discovery platform, announced in March 2008, is one of nine proprietary discovery platforms, to date, that have been developed and validated by Compugen for predictive discovery of drug and diagnostic product candidates... Compugen's Press Release -